TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) has shared an announcement.
Oncoinvent ASA has announced the expiration of the trading period for subscription rights in its fully underwritten rights issue, aimed at raising NOK 130 million through the issuance of 260 million new shares. The rights issue, which supports the company’s ongoing development of its innovative cancer treatment, Radspherin®, will conclude its subscription period on December 1, 2025, with any unsold or unexercised rights lapsing without compensation.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, utilizes radium-224 to target micro-metastases in the peritoneum post-surgery, offering a unique therapeutic approach with promising early clinical efficacy data. The company operates a state-of-the-art manufacturing facility in Oslo and is listed on the Oslo Stock Exchange.
Average Trading Volume: 286,108
Current Market Cap: NOK229.2M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.